Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19.
Patrick S FierYingju XuMarc PoirierGilmar BritoMichelle ZhengRachel S BadeEric SirotaKevin StoneLushi TanGuy R HumphreyDarryl ChangJameson BotheYongqian ZhangFrank BernardoniSteve CastroMichael A ZompaJerry TaylorKevin M SirkAnthony Diaz-SantanaIke DiribeKhateeta M EmersonBharath KrishnamurthiRalph ZhaoMichael WardChengqian XiaoHonggui OuyandJianfeng ZhanWilliam J MorrisPublished in: Organic process research & development (2021)
Herein is described the development of a large-scale manufacturing process for molnupiravir, an orally dosed antiviral that was recently demonstrated to be efficacious for the treatment of patients with COVID-19. The yield, robustness, and efficiency of each of the five steps were improved, ultimately culminating in a 1.6-fold improvement in overall yield and a dramatic increase in the overall throughput compared to the baseline process.